MedPath

Tranexamic Acid Use in Acute Hip Fractures

Phase 4
Completed
Conditions
Acute Hip Fractures
Interventions
Other: Placebo
Registration Number
NCT02947529
Lead Sponsor
Carilion Clinic
Brief Summary

BACKGROUND: Tranexamic acid (TXA) has been used widely for the reduction of post operative blood loss for various orthopaedic procedures including but not limited to total hip arthroplasty and total knee arthroplasty. A recent multihospital meta-analysis conducted in 2013 showed that patients who received TXA showed a significant reduction in post-operative transfusion (20.1% to 7.7%). The procedures the investigators will be evaluating are the intramedullary nail for intertrochanteric fracture and hip hemiarthroplasty. These procedures are similar to the total hip or knee replacement in that they can result in significant blood loss that requires a post operative transfusion.

STUDY PURPOSE: To determine the efficacy of TXA to decrease the rate of post-operative transfusion for acute hip fractures repaired with the following two methods, intramedullary nailing for intertrochanteric fracture and hemiarthroplasty.

METHODS: The model for the study is a prospective randomized control trial. Patients will be placed in one of two arms of the study after passing our inclusion criteria. The arms will be for either the intramedullary nailing for intertrochanteric fracture or for hemiarthroplasty. These two categories will be subdivided into those receiving TXA and those not receiving TXA. The patients in each category will have standard post-operative care and laboratory testing. The investigators will record the patients in either arm of the study, whether it be no TXA or TXA, who require post-operative transfusion within 1 week of the operation.

Detailed Description

This is a prospective randomized control trial. Patients scheduled for either intramedullary nailing for intertrochanteric fractures or for hemiarthroplasty will be selected for the study population.

The proposed research is needed to bridge the gap between the efficacy of TXA in elective, non-emergency procedures (such as total knee arthoplasty and total hip arthroplasty) and its efficacy in emergent acute hip fracture interventions. This study will use intravenous TXA (1g pre-op and 1g post-op) to study its effect on both the reduction of blood loss during intramedullary nail for intertrochanteric fractures and hemiarthroplasty procedures, and the subsequent reduction in the rate of blood transfusion in this patient population.

Both study and control groups will have standard post-operative care and laboratory testing and will be followed for one year post-operatively to record adverse events.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
113
Inclusion Criteria
  • Geriatric patients age 65 or older who require surgery for a low energy trauma hip fracture
Exclusion Criteria
  • Prothrombotic state
  • Cardiac stent within the past year with corresponding antiplatelet therapy
  • Mechanical heart valves
  • Deep vein thrombosis history
  • Aortic stenosis
  • Currently on Coumadin
  • Malignancy
  • Kidney dialysis
  • Non-English speaking patients
  • Medications contraindicated with tranexamic acid.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Hemiarthroplasty - Tranexamic AcidTranexamic AcidPatients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
Intramedullary nail - Tranexamic AcidTranexamic AcidPatients are placed into this arm based on the type of surgery performed and are randomized to receive tranexamic acid
Intramedullary nail - PlaceboPlaceboPatients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
Hemiarthroplasty - PlaceboPlaceboPatients are placed into this arm based on the type of surgery performed and are randomized to receive placebo
Primary Outcome Measures
NameTimeMethod
Transfusion reduction rate1 week

Determine the efficacy of Tranexamic Acid (TXA) in the reduction of allogenic blood transfusion within 1 week following either hemiarthroplasty or intramedullary nailing for intertrochanteric fracture.

Secondary Outcome Measures
NameTimeMethod
Tranexamic acid post operative complications1 year

Determine what effect TXA has on post-operative complications within 1 year following surgery for either hemiarthroplasty or intramedullary nailing for intertrochanteric fracture.

Trial Locations

Locations (1)

Carilion Roanoke Memorial Hospital

🇺🇸

Roanoke, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath